Table 3:

Proportion of patients with response and duration of responses by tumour type according to investigator assessment

	Patients	Patients with response	Median duration of response, months*
Overall	153	121 (79%, 72–85)	35·2 (22·8–NE)
Soft tissue sarcoma
Infantile fibrosarcoma	28	27 (96%, 82–100)	NE (NE–NE)
Gastrointestinal stromal tumour	4	4 (100%, 40–100)	26·3 (7·6–26·3)
Other	36	29 (81%, 64–92)	NE (10·1–NE)
Thyroid	24	19 (79%, 58–93)	NE (14·8–NE)
Salivary gland	20	18 (90%, 68–99)	35·2 (13·3–NE)
Lung	12	9 (75%, 43–95)	NE (NE–NE)
Colon	8	4 (50%, 16–84)	3·7 (3·7–NE)
Melanoma	7	3 (43%, 10–82)	NE (3·7–NE)
Breast	4	3 (75%, 19–99)	NE (NE–NE)
Bone sarcoma	2	1 (50%, 1–99)	7·7 (NE–NE)
Cholangiocarcinoma	2	1 (50%, 1–99)	7·3 (NE–NE)
Pancreas	2	1 (50%, 1–99)	3·5 (NE–NE)
Appendix	1	0 (NC)
Congenital mesoblastic nephroma	1	1 (100%, 3–100)	NE (NE–NE)
Hepatocellular	1	0 (NC)
Unknown primary	1	1 (100%, 3–100)	NE (NE–NE)

Data are n, n (%, 95% CI), or median (95% CI). NC=not calculable. NE=not estimable.

^*In patients with confirmed responses (n=108).